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Mass Spectrometry (MS)-based phosphoproteomics tools are crucial for understanding the structure and dynamics
of signaling networks. Approaches such as affinity purification followed by MS have also been used to elucidate
relevant biological questions in health and disease.
The study of proteomes and phosphoproteomes as linked systems, rather than research studies of individual
proteins, are necessary to understand the functions of phosphorylated and un-phosphorylated proteins under
spatial and temporal conditions. Phosphoproteome studies also facilitate drug target protein identification which
may be clinically useful in the near future.
Here, we provide an overview of general principles of signaling pathways versus phosphorylation. Likewise, we
detail chemical phosphoproteomic tools, including pros and cons with examples where these methods have been
applied. In addition, basic clues of electrospray ionization and collision induced dissociation fragmentation are
detailed in a simple manner for successful phosphoproteomic clinical studies.
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Proteomics technologies are of great use for developing
reference maps of targets of kinase inhibitors. This im-
plies a difficult but promising issue, as it concerns the
determination of the network-level response to different
inhibitor treatments. The challenges and cautions asso-
ciated with each method will be described in a simple
manner.
With advances of techniques available, the next decade
should see a rapid increase in our understanding of sig-
naling network regulation. This, at the same time, im-
plies more efficient therapeutic strategies.
Comparative proteomics can distinguish small but im-
portant changes in protein modifications in their struc-
ture, thus facilitating drug target protein identification.
In addition, phosphoproteomic approaches can be
exploited to monitor changes in phosphorylation events
in order to characterize drug actions on cell signaling
pathways and/or signaling cascades. Likewise, functional
proteomic and phosphoproteomic approaches can be* Correspondence: Elena.lopez.villar@gmail.com
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in any medium, provided the original work is pused to: (i) improve the knowledge or the clarification of
the mechanism of a drug action for a specific disease,
(ii) achieve relevant protein-identification of disease
related to a specific signaling network and (iii) reach the
important step of innovation of novel drug targets for
specific pathologies [1].
In spite of all these uses of proteomics and phospho-
proteomics, there is limited clinical success of therapeu-
tics targeting cellular signaling processes owing to the
complex feedback regulation encoded within the signal-
ing network. Signaling networks are controlled mainly
by phosphorylation.
When a protein is phosphorylated, this implies that
the protein structure contains a phosphate group. It
should be assumed that the phosphate group assign-
ments -during phosphoproteomic studies- in a low
expressed phosphorylated protein (e.g. some kinases)
imply difficulties such as: (a) the low abundance of those
signaling molecules within cells, (b) the stress/stimulation
time-duration, as only a small fraction of phosphory-
lated kinases are available at any given time as a result
of a stimulus, (c) and, the time adaptation over signaling
pathways is a relevant and fast factor for kinases phos-
phorylation. It should be taken into account that then Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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cessful to purify phosphopeptides from highly expressed
proteins [2].
Proteomics undoubtedly holds great promise for disease
diagnosis, prognosis and prediction of therapeutic outcome
on an individualized basis. However, proper study design is
always necessary to optimize and establish the right prote-
omic strategy for each clinical sample to be studied. The
resulting data must, in addition, be evaluated by scientists
and clinicians. Figure 1 illustrates a possible proteomic
work-flow useful for clinical studies.
Importance of phosphoproteomics for signal
transduction pathways
Protein phosphorylation events often play important roles
in broad signaling networks within a cell. Phosphorylation
of kinases frequently regulates their own activity, but they
are commonly under-represented in phosphoproteomic
studies. This is due, in part, to their low expression within
the cell and in part due to the difficulty in detecting highly
negatively charged peptides in the mass spectrometer.
Nevertheless, this drawback can be overcome though
kinase affinity purification techniques that enrich for
these low expressed proteins.
Phosphatases also play important roles in regulating
signaling pathways through the removal of phosphateFigure 1 A possible proteomic work-flow for clinical studies. For ident
and enzimatically digested to extract peptides for further analysis by MS. Th
measured by a mass spectrometer. Data-computer analysis is carried out w
validation of identified protein, interpretation and classification of the prote
composition.groups from proteins. In fact depleting cells of specific
protein phosphatases and using phosphoproteomic
approaches, can determine which proteins are regulated
by the phosphatase of interest [2-7].
General principles of signaling pathways versus
phosphorylation
Phosphorylation is the addition of a phosphate (PO4
3-)
group to a protein or another organic molecule. Phos-
phorylation turns many protein enzymes “on” and “off”,
thereby altering their function and activity. Protein
phosphorylation in particular plays a significant role in a
wide range of cellular processes. On the other hand, re-
versible phosphorylation of proteins is an important
regulatory mechanism that occurs in both prokaryotic
and eukaryotic organisms [8-14].
Within a protein, phosphorylation can occur on sev-
eral amino acids. Phosphorylation on serine is the most
common, followed by threonine. Tyrosine phosphoryl-
ation is relatively rare. However, since tyrosine phos-
phorylated proteins are relatively easy to purify using
antibodies, tyrosine phosphorylation sites are relatively
well understood. Histidine and aspartate phosphoryl-
ation occurs in prokaryotes as part of two-component
signaling and in some cases in eukaryotes in some signal
transduction pathways [15].ification, in-gel or in-solution proteins of interest are excised, washed
e mass to charge (m/z) ratio of the retained peptides can be
hich mainly includes: identification and classification of proteins,
in lists, structural analysis of proteins, PTM analysis and Cellular
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dephosphorylate proteins. Many enzymes and receptors
are switched "on" or "off" by phosphorylation and
dephosphorylation. Reversible phosphorylation results in
a conformational change in the structure of many
enzymes and receptors, causing them to become activated
or deactivated. Phosphorylation usually occurs on serine,
threonine, tyrosine and histidine residues in eukaryotic
proteins. Histidine phosphorylation of eukaryotic proteins
appears to be much more frequent than tyrosine phos-
phorylation. In prokaryotic proteins phosphorylation
occurs on the serine, threonine, tyrosine, histidine or ar-
ginine or lysine residues [16,17].
The addition of a phosphate (PO4) molecule to a polar
group of an amino acid residue can turn a hydrophobic
portion of a protein into a polar and extremely hydro-
philic portion of molecule. Thus, it can introduce a con-
formational change in the structure of the protein via
interaction with other hydrophobic and hydrophilic resi-
dues in the protein. Upon the deactivating signal, the
protein becomes dephosphorylated again and stops
working. This is the mechanism in many forms of signal
transduction.
The regulatory roles of phosphorylation include [18-25]:
(a) Biological thermodynamics of energy-requiring
reactions (for example, phosphorylation of Na+/
K+-ATPase during the transport of sodium (Na+)
and potassium (K+) ions across the cell membrane
in osmoregulation to maintain homeostasis of the
body's water content).
(b) Mediates enzyme inhibition (for example,
phosphorylation of the enzyme GSK-3 by AKT
(Protein kinase B) as part of the insulin signaling
pathway)
(c) Protein-protein interaction via "recognition
domains." (for example, phosphorylation of the
cytosolic components of NADPH oxidase, a large
membrane-bound, multi-protein enzyme present in
phagocytic cells, plays an important role in the
regulation of protein-protein interactions in the
enzyme)
(d) Protein degradation - for example, in the late 1990s,
it was recognized that phosphorylation of some
proteins causes them to be degraded by the ATP-
dependent ubiquitin/proteasome pathway. These
target proteins become substrates for particular E3
ubiquitin ligases only when they are phosphorylated.
Important issues of eukaryotic signaling pathways [5-26]
are:
When an extracellular signal is generated to induce a
kinase cascade, it is often transmitted into the cell
through receptors that are either kinases themselves, orthrough kinases associated with receptors. Often, the ac-
tivation of multiple signal cascades by (a) receptors,
(b) different protein PTMs, (c) crosstalk between signal-
ing pathways and (d) feedback loops to ensure optimal
signaling output and modulation (Figure 2).
(a)MAPK are a family of Ser/Thr protein kinases,
which are widely conserved among eukaryotes, and
are involved in many cellular programs. These
programs are related to: cell proliferation, cell
differentiation, cell movement, and cell death.
MAPK signaling cascades are organized
hierarchically into three-tiered modules. Moreover,
MAPKs are phosphorylated and activated by
MAPK-kinases (MAPKKs), which in turn are
phosphorylated and activated by MAPKK-kinases
(MAPKKKs). In addition, the MAPKKKs are in turn
activated by interaction with the family of small
GTPases and/or other protein kinases, connecting
the MAPK module to cell surface receptors or
external stimuli.
(b)The binding of receptor Tyrosine (Tyr) kinases
(RTKs) to their cognate ligands at the cell surface
results in receptor dimerization and
autophosphorylation. Phosphorylated Tyr residues
subsequently serve as docking sites to recruit
signaling mediators, such as growth factor receptor-
bound protein 2 (GRB2).
(c) The best studied mitogen activated protein kinases
(MAPKs) are the extracellular signal regulated
protein kinases (ERK). ERKs phosphorylate
cytoplasmic targets that then migrate to the nucleus
where they can activate transcription factors
involved in cellular proliferation. ???
(d)As a general view of the orchestrated signaling
pathways, it is important to know that followed by
communication of the signal to different cellular
compartments are (i) signal processing and (ii)
amplification by plasma membrane proximal events.
(e)Multiple signaling cascades such as (i) the
phosphoinositide-3 kinase (PI3K)-AKT, (ii) Ras-Raf-
extracellular signal-regulated kinase (ERK) mitogen-
activated protein kinase (MAPK), and (iii) signal
transducer and activator of transcription (STAT)
pathways are activated by the assembly of these
signaling complexes.
On the other hand, (iiii) Casitas B-lineage
lymphoma (CBL)-mediated ubiquitylation of RTKs
controls their endocytosis and the duration of
receptor signaling. In addition, binding of tumour
necrosis factor-? (TNF?) to its receptor, TNFR1,
induces trimerization of the receptor and
recruitment of the adaptor protein TNFR1-
associated death domain (TRADD).
Figure 2 Scheme of the three-tiered modules of the mitogen-activated protein kinases (MAPK) in eukaryotic cells. MAPK signaling
cascades are organized hierarchically into three-tiered modules (a) (b) and (c). MAPKs are phosphorylated and activated by MAPK-kinases
(MAPKKs), which in turn are phosphorylated and activated by MAPKK-kinases (MAPKKKs). MAPKKKs are in turn activated by interaction with the
family of small GTPases and/or other protein kinases, connecting the MAPK module to cell surface receptors or external stimuli.
Phosphoproteomics strategies allow identification of several phosphorylated proteins at a given time and space, thus it is possible to study the
dynamic processes of signaling networks via phosphoproteomic MS-based tools (GPCR: G-protein coupled receptor).
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multiprotein signaling complex containing TNFR-
associated factor 2 (TRAF2), receptor interacting
Ser/Thr protein kinase 1 (RIPK1) and nuclear
factor-κB (NF-κB) essential modulator (NEMO).
The result is the activation of different signaling
networks, such as the ERK MAPK, p38 MAPK
and NF-κB pathways. Proteins in the MAPK
signaling pathways are activated by both RTKs
and TNF?, which allows cells to integrate
multiple signals [26-38].
Figure 2 illustrates a scheme of the three-tiered modules
of the mitogen-activated protein kinases (MAPK) in
eukaryotic cells.
It is important to remark that explaining complex sig-
naling pathway phosphorylation events can be difficult.
In cellular signaling pathways, a protein A phosphory-
lates protein B, and B phosphorylates C. However, in
another signaling pathway, protein D phosphorylates A,
or phosphorylates protein C. Global approaches such as
phosphoproteomics, the study of phosphorylated pro-
teins, which is a sub-branch of proteomics, combined
with mass spectrometry-based proteomics, have been
utilized to identify and quantify dynamic changes in
phosphorylated proteins over time and space. These
techniques are becoming increasingly important for
the systematic analysis of complex phosphorylation
networks.Current phosphoproteomic MS-based approaches:
pros and cons of current and most used
methodologies for the detection of
phosphorylated proteins
Current phosphoproteomic approaches
Several analytical techniques exist for the analysis of
phosphorylation, e.g., Edman sequencing and 32P-phos-
phopeptide mapping for localization of phosphorylation
sites. Unfortunately, these methods do not allow high-
throughput analysis or imply very labour intense operations
[39]. The advantage of using the MS tools, is that high-
throughput analysis of phosphorylated protein residues can
be developed [40,41]. On the other hand, phosphospecific
antibodies are routinely used to immunoprecipitate and
therefore to enrich in phosphorylated proteins from
complex mixtures [42]. A disadvantage is that cur-
rently, there are no commercial available antibodies
that are suitable for faithfully enriching all proteins
that are phosphorylated. Thus, these proteins must be
purified or enriched from complex mixtures using alterna-
tive methods [43].
Carrying out in-gel or in-solution trypsin digestion
of protein complex mixtures [44], the resulted phos-
phopeptides and non-phosphopeptides can be loaded
into different metal ion chromatography (e.g. Immobi-
lized Metal ion Affinity Chromatography IMAC (Fe3+),
and Titanium Dioxide TiO2 [45]), in order to enrich in
phosphopeptides. The enriched solution can also be
submitted into different reverse-phase chromatography
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to clean and desalt those phosphopeptides previously
eluted. Moreover, all these kinds of chromatographies
will reduce the suppression of phosphorylated peptides
in the mass spectra.
When using IMAC (Fe3+) and also (TiO2) [45], the
negatively charged phosphopeptides are purified by their
affinity to positively charged metal ions, but some of
these methods suffer the problem of binding acidic,
non-phosphorylated peptides. Ficarro and co-workers
[40] circumvented this problem on IMAC (Fe3+) by con-
verting acidic peptides to methyl esters. Unfortunately,
methyl-esterification increases the spectra complexity
and requires lyophilization of the sample, causing ad-
sorptive losses of, in particular, phosphopeptides [46,47].
Ficarro et al., [40] were able to sequence hundreds of
phosphopeptides from yeast, including Slt2p kinase, but
the level of phosphorylated residues identified from
kinases were low compared to those from phosphopro-
teins highly expressed within the cell. Recently, TiO2
chromatography using 2,5-dihydroxybenzoic acid (DHB)
was introduced as a promising strategy by Larsen et al.,
[45]. TiO2/DHB resulted in a higher specificity and yield
as compared to IMAC (Fe3+) for the selective enrich-
ment of phosphorylated peptides from model proteins
(e.g. lactoglobulin bovine, casein bovine).
Chiefly phosphopeptides from highly expressed proteins
within cells can be purified, while those from phosphory-
lated proteins with low level expression (e.g. kinases)
do not bind so well to those resins. This is due to the
low proportion of this kind of protein, or on the other
hand, their available amount binds to metal ions al-
though it is not sufficient to be detected by MS. The
combination of Strong Cation Exchange Chromatog-
raphy (SCX) with IMAC (Fe3+) has been proven on
yeast, resulting in a huge number of phosphorylated
residues identified (over 700 including Fus3p kinase)
[41]. Although more than 100 signaling proteins and
functional phosphorylation sites were identified, in-
cluding receptors, kinases and transcription factors, it
was clear that only a fraction of the phosphoproteome
was revealed [41-48].
It is clear that methodologies to enrich for phosphory-
lated residues from kinases should be improved. How-
ever, this is not straightforward for several reasons: (a)
the low abundance of those signaling molecules within
cells, (b) the stress/stimulation time-duration, as only a
small fraction of phosphorylated kinases are available at
any given time as a result of a stimulus. Also, (c) the
time adaptation over signaling pathways is a relevant
and fast factor for kinases phosphorylation, and (d) the
current phosphoenrichment methods, which are mainly
successful for purifying phosphopeptides from highly
expressed proteins [49-51].When peptide ions are fragmented via Collision
Induced Dissociation (CID), series of y- and b- ions are
formed [52,53]. The peptide sequence of these peptides
is obtained by correlating mass difference between peaks
in the y-ion series or between peaks in the b-ion series
with amino acid residue masses.
The CID fragmentation mainly occurs on the pep-
tide backbone, and sequence information is obtained.
Related to phosphotyrosine residues, partial neutral
loss is observed (HPO3, 80 m/z) in MS2 mode, and
the phosphate group on tyrosine (Tyr) residues is
more stable than on serine (Ser) and threonine (Thr)
residues. Also, the phospho-finger-print characteristic
of phosphotyrosine is the phosphotyrosine immonium
ion (~216 Da) [54,55]. Via MS3 mode, the ion ori-
ginating from neutral loss (NL) of phosphoric acid
(H3PO4) can be selected for further fragmentation.
Then, the selected ion is automatically selected for
further fragmentation after neutral loss fragmenta-
tion. Therefore, it is possible to add extra energy for
the fragmentation of peptide backbone.
Nevertheless, the MS3 mode requires that the phosphor-
ylation on ser and thr residues be labile and conventional
fragmentation via CID commonly results in the partial NL
of H3PO4, (98 m/z) in MS2 mode. This is due to the gas
phase β-elimination of the phosphor-ester bond and thus,
dehydroalanine (Ser ~69 Da) and dehydro-2-aminobutyric
acid (Thr ~83 Da) are generated [54,55].
Alternative phosphopeptide enrichment strategies
Phosphopeptides can be de-protected and sampled
under acidic conditions. BEMA (β-elimination/Michael
addition) takes advantage of (a) the ease of β-elimination
of phosphorylated Ser and Thr residues at basic pH, and
(b) the ability to subject the resulting dehydroalanine/
methyl-dehydroalanine products to Michael addition
with a desired tag for affinity purification [56-58].
In addition, Calcium phosphate precipitation (CPP)
has been proven to be a fast, economical, and simple en-
richment technique [59] in exchange for diminished spe-
cificity. Moreover, PhosphorAmidate Chemistry (PAC) is
another important approach in which phosphopeptides
are coupled to a solid-phase support such as an amino-
derivatized dendrimer or controlled-pore glass deriva-
tized with maleimide for selection [60,61]. Figure 3 illus-
trates the most important pros and cons of several
phosphoproteomic-based MS tools.
Tandem MS methodology -basic issues- useful for
phosphoproteomics via electrospray ionization (ESI)
ESI consists of a liquid-phase ion source in which the
non-volatile analyte molecules are analyzed directly from
the liquid phase. The development of electrospray
ionization for the analysis of biological macromolecules
Figure 3 Pros and cons of the most useful phosphoproteomic -MS based tools. Generally, immunoprecipitation of Tyrosine via antibodies,
is more efficient than antibody immunoprecipitation of Serine and Threonine residues. On the other hand, affinity chromatography of IMAC and
TiO2, is more efficient for isolating phosphorylated residues of Serine and Threonine than Tyrosine. Moreover, TiO2 has shown higher specificity
when it is coupled to DHB than IMAC. In addition, IMAC has shown higher specificity when converting non-phosphorylated residues (acidic
peptides) to methyl esters, but the complexity of spectra increases. Furthermore, SCX, SAX and calcium phosphate precipitation methods, are
more efficient when coupled to IMAC and/or TiO2 for clinical phosphoproteomic studies.
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Chemistry to John Bennett Fenn in 2002.
Firstly, the analyte molecules are diluted in an aqueous
solution, and secondly this aqueous solution is forced via a
fine capillary at a very low flow rate (0.1-10 μL/min).
The liquid containing the analyte(s) of interest is dis-
persed by electrospray into a fine aerosol. Because the
ion formation involves extensive solvent evaporation,
the typical solvents for electrospray ionization are pre-
pared by mixing water with volatile organic compounds
(e.g. methanol, acetonitrile).
To decrease the initial droplet size, compounds that
increase the conductivity (e.g. acetic acid) are customar-
ily added to the solution. Large-flow electrosprays can
benefit from additional nebulization by an inert gas such
as nitrogen. In addition, the aerosol is sampled into the
first vacuum stage of a mass spectrometer through a ca-
pillary, which can be heated to aid further solvent evap-
oration from the charged droplets. Moreover, the solvent
evaporates from a charged droplet until it becomes un-
stable upon reaching its Rayleigh limit. At this point, the
droplet deforms and emits charged jets in a process
known as Coulomb fission. After all these steps and during
the fission, the droplet loses a small percentage of its mass
(1.0-2.3%) along with a relatively large percentage of its
charge (10-18%) [62-64]. Figure 4 illustrates the electro-
spray ionization process in a simple manner.
As a general rule, during MS-based experiments, a
phosphopeptide mixture is separated using capillary li-
quid chromatography (LC). A typical separation column
is 25 to 100 microns in diameter and 5 to 30 cm inlength. The eluent is concurrently introduced into the
mass spectrometer via electrospray ionization (ESI) or
nanospray, which is a derivative of ESI.
ESI is a process that generates multiply protonated gas-
phase peptide cations. The mass-to-charge ratio (m/z) and
intensity (I) of the intact peptide precursors are recorded
by an initial MS scan – commonly referred to as a full scan
MS. Then, m/z values for peaks (list of masses) with high
intensity are automatically selected in order of decreasing
abundance for sequencing by tandem MS (MS/MS).
This process of precursor selection, dissociation, and
fragment ion mass analysis is repetitively performed on
analyte species as they elute from the LC column.
Ideally, MS/MS interrogation of a phosphorylated pep-
tide generates a series of fragment ions that differ in
mass by a single amino acid, so that the peptide primary
sequence and position of the phosphorylated modifica-
tions can be determined. This necessitates peptide bond
cleavage that is not only specific to the peptide back-
bone, but is robust enough to elucidate differences in
peptides whose primary amino acid sequences are the
same, yet vary in the site of phosphorylation (e.g., positional
isomers) [65].
The dominant NL peak in the fragmentation spectra
of phosphopeptides obtained via traditional Collision
Induced Dissociation (CID) has received much attention
[66-68]. The NL peak can easily suppress sequence diag-
nostic ion peaks causing identification of the peptide to
become very difficult and sometimes impossible.
Ion traps are the most common mass spectrometers of
performing phosphoproteome analyses in CID mode.
Figure 4 Illustration in a simple manner of the electrospray ionization process. The analyte solution is forced through the capillary, which has been
supplied with high voltage. A Taylor cone is created due to the electric field between the capillary and the counter electrode, forming charged droplets of
analyte ions and solvent. As these droplets travel towards the mass spectrometer the solvent evaporates creating analyte ions. When the solution that
comprises the Taylor cone reaches the Rayleigh limit, at which point the Coulombic repulsion of the surface charge is equal to the surface tension of the
solution, charged droplets are formed at the tip of the capillary. (Courtesy TE Tingholm Master Thesis 2005, PR Group, Odense Univ. Denmark).
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such as (a) NL triggered MS3 or (b) multistage activa-
tion (MSA), which alleviate the neutral loss issue com-
monly found with such instrumentation. NL MS3 and
MSA methods allow fragmenting of the NL peak of the
precursor ion further, in order to generate more back-
bone cleavages. These “extra” generated backbone clea-
vages, then form the more diagnostic source for peptide
sequencing [69-71].
Alternatively, Electron transfer dissociation (ETD) and
electron capture dissociation (ECD) have also shown
great promise since the phosphate group remains
attached during and after activation. Many detected
phosphopeptides contain multiple Ser/Thr/Tyr residues
representing the likely possibility that there is more than
one possible location for the site of phosphorylation
within the peptide. The abundant NL observed in low
energy CID can hamper the correct assignment of the
phosphor-sites in such peptides. Thus, a concerted effort
has been made to understand, in detail, the rules of
phosphopeptide fragmentation [72-76]. Finally, it must
be said that the resulting proteomic-MS based data is
pooled via bioinformatic tools, therefore, it is easier to
interpret the biological and clinical meaning [77,78].Conclusions
(a) Phosphorylation is a key reversible modification
that regulates protein function, sub-cellular
localization, complex formation, degradation of
proteins and therefore cell signaling networks. It
can be assumed that up to 30% of all proteins
may be phosphorylated, some, multiple times.
Thus, it implies that phosphorylated proteins
within the cell are important targets to be
studied in order to improve the knowledge of
many diseases.
(b)Phosphoproteomics is a branch of proteomics that
identifies, catalogs, and characterizes proteins
containing a phosphate group. Moreover,
phosphoproteome analysis provides clues on which
protein or pathway might be activated. This is due
to that a change in phosphorylation status almost
always reflects a change in protein activity. Indeed,
it can indicate which proteins might be potential
drug targets as exemplified by the kinase inhibitor.
Furthermore, while phosphoproteomics will greatly
expand knowledge about the numbers and types of
phosphoproteins; its greatest promise is the rapid
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networks.
(c) Elucidating complex signaling pathway
phosphorylation events can be difficult and
laborious. Global approaches such as
phosphoproteomics, combined with different MS
strategies, have been and are being utilized to
identify dynamic changes in phosphorylated proteins
over time and space. These techniques are
becoming increasingly important for the systematic
analysis of complex phosphorylation networks, so
important for clinical issues. Moreover, clinical
PTMs research studies coupled to bioinformatics
tools are currently and successfully being used and
will elucidate relevant clues, useful for improving
diagnoses and thererapies.
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